% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Yang:120555,
      author       = {R. Yang and S. Stöcker$^*$ and S. Schott and J. Heil and
                      F. Marme and K. Cuk$^*$ and B. Chen$^*$ and M. Golatta and
                      Y. Zhou and C. Sutter and B. Wappenschmidt and R. Schmutzler
                      and P. Bugert and B. Qu and C. R. Bartram and C. Sohn and A.
                      Schneeweiss and B. Burwinkel$^*$},
      title        = {{T}he association between breast cancer and {S}100{P}
                      methylation in peripheral blood by multicenter case-control
                      studies.},
      journal      = {Carcinogenesis},
      volume       = {38},
      number       = {3},
      issn         = {1460-2180},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-00984},
      pages        = {312 - 320},
      year         = {2017},
      abstract     = {Breast cancer (BC) is the leading cancer in women
                      worldwide. Changes in DNA methylation in peripheral blood
                      could be associated with malignant diseases. Making use of
                      screening results by llumina 27K Methylation Assay, we
                      validated demethylation of five CpG sites of S100P gene in
                      blood cell DNA of BC patients by three independent
                      retrospective studies with subjects from different centers
                      (Validation I: 235 familial BC case and 206 controls, odds
                      ratio per $-1\%$ methylation > 1.03, and P < 6.00 × 10-8
                      for all five CpG sites; Validation II: 189 sporadic BC case
                      and 189 controls, odds ratio per $-1\%$ methylation > 1.03,
                      P < 8.0 × 10-5 for four CpG sites; Validation III: 156
                      sporadic BC case and 151 controls, odds ratio per $-1\%$
                      methylation > 1.03, P < 6.0 × 10-4 for four CpG sites). In
                      addition, the blood-based S100P methylation pattern was
                      similar among BC patients with differential clinical
                      characteristics regardless of stage, receptor status and
                      menopause status. The observed BC-associated decreased S100P
                      methylation in blood mainly originates from the leucocytes
                      subpopulations but not B cells. The methylation levels of
                      most S100P CpG sites were inversely correlated with the
                      expression of S100P in leucocytes (P < 1.2 × 10-4) and in
                      tissue (P < 1.1 × 10-4). This study reveals significant
                      association between blood-based decreased S100P methylation
                      and BC, and provides another proof for the application of
                      altered DNA methylation signatures from blood cells as
                      potential markers for the detection of BC, especially for
                      the early stage.},
      cin          = {C080 / C050 / V964},
      ddc          = {610},
      cid          = {I:(DE-He78)C080-20160331 / I:(DE-He78)C050-20160331 /
                      I:(DE-He78)V964-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28426874},
      doi          = {10.1093/carcin/bgx004},
      url          = {https://inrepo02.dkfz.de/record/120555},
}